Financial Performance Summary

Income Statement Highlights (Consolidated, Rs. Crores)

  • Revenue from Operations: Rs 4,336 crore, up 10% YoY from Rs 3,942 crore (Q1FY26)
  • Total Income: Rs 4,391 crore, up 9% YoY from Rs 4,022 crore (Q1FY26)
  • EBITDA: Rs 902 crore, up 7% YoY from Rs 846 crore (Q1FY26)
  • EBITDA Margin: 21% (consistent with Q1FY26)
  • Net Profit Before Exceptional Items: Rs 145 crore, up 245% YoY from Rs 42 crore (Q1FY26)
  • Net Profit (Reported): Rs 141 crore, up 355% YoY from Rs 31 crore (Q1FY26)
  • EPS: Rs 0.9 compared to Rs 0.3 in Q1FY26

Business Segment Performance

Biopharma Business:

  • Total Revenue: Rs 3,615 crore, up 17% YoY from Rs 3,088 crore
  • Biosimilars: Rs 2,855 crore, up 16% YoY
  • Generics: Rs 760 crore, up 21% YoY from Rs 630 crore

Services Business:

  • Revenue: Rs 736 crore, down 16% YoY from Rs 875 crore

Expense Analysis

  • Material & Power Costs: Rs 1,599 crore, up 6% YoY
  • Staff Costs: Rs 868 crore, up 2% YoY
  • R&D Expenses: Rs 240 crore, up 17% YoY from Rs 205 crore
  • Interest & Finance Charges: Rs 213 crore, down 23% YoY from Rs 277 crore
  • Depreciation & Amortization: Rs 548 crore, up 20% YoY from Rs 455 crore

Exceptional Items

  • Exceptional items net: Rs (13) crore in Q1FY27 compared to Rs (17) crore in Q1FY26
  • Exceptional items net of tax: Rs (4) crore in Q1FY27 compared to Rs (11) crore in Q1FY26

Business Updates and Operational Highlights

Product Launches and Regulatory Approvals

North America:

  • Launched Bosaya™ and Aukelso™ (biosimilar Denosumab) in the U.S.
  • Commercialized Yesafili™ (biosimilar Aflibercept) as interchangeable biosimilar in August 2026
  • Commercialized generic Liraglutide in the U.S.
  • Secured Health Canada Notice of Compliance for Yesintek® (biosimilar Ustekinumab) autoinjector pen

Europe:

  • Commercialized Evfraxy® (biosimilar Denosumab) across multiple European markets
  • Commercialized Abevmy® (biosimilar Bevacizumab) in Czech Republic and Switzerland

Emerging Markets:

  • Secured approval for Yesafili™ as Malaysia's first biosimilar Aflibercept
  • Maintained market leadership for biosimilar Bevacizumab franchise in Brazil

Manufacturing and Capacity Expansion

  • Received EMA approval for new drug product fill-finish plant for insulins in Malaysia

Services Business Developments

  • Signed MoU with BRIC-Translational Health Science and Technology Institute (THSTI) for clinical development and translational research
  • Strengthened Syn.AI platform with giga scale virtual screening capabilities for drug discovery

Leadership Commentary

Kiran Mazumdar-Shaw, Executive Chairperson:

Emphasized focus on translating strategic investments into sustainable growth, citing favorable biosimilars policy environment and expanded U.S. manufacturing capabilities. Expressed confidence in North American market opportunities and research services business investments.

Shreehas Tambe, CEO & Managing Director:

Highlighted resilient performance with 10% revenue growth and successful launch of multiple products in U.S. market. Noted 23% reduction in interest costs through balance sheet optimization and expected accelerated growth momentum through the year.

Siddharth Mittal, CEO & Managing Director, Syngene International:

Outlined immediate priorities to sharpen commercial execution, strengthen delivery, build cost-competitive organization, and invest in CDMO, AI, and differentiated scientific capabilities.

Corporate Governance Updates

  • Bobby Parikh completed term as Independent Director effective July 22, 2026
  • Nicholas Haggar to complete term as Independent Director after 48th AGM on August 6, 2026

Balance Sheet Position (as of June 30, 2026)

  • Total Assets: Rs 64,696 crore (vs Rs 63,651 crore as of Mar 31, 2026)
  • Property, Plant and Equipment: Rs 9,302 crore
  • Capital Work-in-Progress: Rs 4,885 crore
  • Goodwill: Rs 18,579 crore
  • Cash and Cash Equivalents: Rs 1,518 crore (vs Rs 2,417 crore as of Mar 31, 2026)
  • Total Borrowings: Rs 14,953 crore (Non-current: Rs 10,600 crore, Current: Rs 4,353 crore)
  • Total Equity: Rs 37,546 crore

Forward-looking Statements

The document contains customary forward-looking statements subject to risks including economic conditions, regulatory changes, competition, currency fluctuations, and political conditions.

Investor Communication

Earnings call scheduled for August 6, 2026 at 10:00 AM IST via Zoom webinar.